In the last trading session, 1.33 million Cytokinetics Inc (NASDAQ:CYTK) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $43.28 changed hands at -$1.63 or -3.63% during last session, the market valuation stood at $5.12B. CYTK’s last price was a discount, traded about -74.93% off its 52-week high of $75.71. The share price had its 52-week low at $40.53, which suggests the last value was 6.35% up since then. When we look at Cytokinetics Inc’s average trading volume, we note the 10-day average is 1.45 million shares, with the 3-month average coming to 1.54 million.
Analysts gave the Cytokinetics Inc (CYTK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.32. If we narrow down to specifics, the data shows that 0 out of 12 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CYTK as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Cytokinetics Inc’s EPS for the current quarter is expected to be -1.36.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Instantly CYTK was in red as seen at the end of in last trading. With action -2.52%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.99%, with the 5-day performance at -2.52% in the red. However, in the 30-day time frame, Cytokinetics Inc (NASDAQ:CYTK) is -6.24% down. Looking at the short shares, we see there were 14.07 million shares sold at short interest cover period of 7.66 days.
The consensus price target for the stock as assigned by Wall Street analysts is 93.5, meaning bulls need an upside of 53.71% from its current market value. According to analyst projections, CYTK’s forecast low is 67 with 120 as the target high. To hit the forecast high, the stock’s price needs a -177.26% plunge from its current level, while the stock would need to soar -54.81% for it to hit the projected low.
Cytokinetics Inc (CYTK) estimates and forecasts
Year-over-year growth is forecast to reach 92.03% up from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 3.09M. 14 analysts are of the opinion that Cytokinetics Inc’s revenue for the current quarter will be 3.44M. The company’s revenue for the corresponding quarters a year ago was 835k and 249k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 270.16%. The estimates for the next quarter sales put growth at 1,280.75%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.02%. The 2025 estimates are for Cytokinetics Inc earnings to decrease by -8.67%, but the outlook for the next 5-year period is at 19.31% per year.
CYTK Dividends
Cytokinetics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.47% of Cytokinetics Inc shares while 114.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 115.25%. There are 114.71% institutions holding the Cytokinetics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 14.3958% of the shares, roughly 14.67 million CYTK shares worth $794.97 million.
FMR LLC holds the second largest percentage of outstanding shares, with 11.3056% or 11.52 million shares worth $624.32 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Vanguard Specialized-Health Care Fund and iShares Core S&P Midcap ETF . With 4.07 shares estimated at $176.06 million under it, the former controlled 3.44% of total outstanding shares. On the other hand, iShares Core S&P Midcap ETF held about 3.25% of the shares, roughly 3.85 shares worth around $166.69 million.
